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Abstract
INTRODUCTION: Proliferation and apoptosis are opposing processes by which
the cell numbers are kept in a delicate balance, essential for tissue homeostasis,
whereas uncontrolled growth of cells is a hallmark of cancer. Papillary thyroid
cancer (PTC) is the commonest type of thyroid cancer, with some PTC
following an indolent course, whereas the other ones are more aggressive.
AIM: To evaluate respective contribution of proliferation and apoptosis in the
tumorigenesis of PTC by automated analysis. MATERIALS AND METHODS: We
investigated the immunolabeling of phosphorylated histone H3 (pHH3), cyclin D1,
active caspase-3, and bcl-2 in thirteen cases each of metastatic PTC, follicular
variant of PTC (FVPTC), papillary microcarcinoma (PMC) and well differentiated
tumor of uncertain malignant potential (WDT-UMP). FVPTC cases comprised
seven encapsulated and six unencapsulated cases. RESULTS: Proliferation, as
assessed by pHH3 and cyclin D1 immunolabeling, was increased in all PTC
variants, ...
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Proliferation and apoptosis are opposing processes by which the cell numbers are kept in a
delicate balance, essential for tissue homeostasis, whereas uncontrolled growth of cells is a
hallmark of cancer. Papillary thyroid cancer (PTC) is the commonest type of thyroid cancer,
with some PTC following an indolent course, whereas the other ones are more aggressive.
Aim
To evaluate respective contribution of proliferation and apoptosis in the tumorigenesis of
PTC by automated analysis.
Materials and Methods
We investigated the immunolabeling of phosphorylated histone H3 (pHH3), cyclin D1,
active caspase-3, and bcl-2 in thirteen cases each of metastatic PTC, follicular variant of
PTC (FVPTC), papillary microcarcinoma (PMC) and well differentiated tumor of uncertain
malignant potential (WDT-UMP). FVPTC cases comprised seven encapsulated and six
unencapsulated cases.
Results
Proliferation, as assessed by pHH3 and cyclin D1 immunolabeling, was increased in all
PTC variants, including the putative precursor lesion WDT-UMP, compared to normal thy-
roid tissue. pHH3 was immunolabeled in more cells of metastatic PTC than of PMC and of
encapsulated FVPTC. Surprisingly, metastatic PTC and unencapsulated FVPTC also dem-
onstrated more cleaved caspase-3 immunolabeled cells than the other types. In contrast,
increased expression of bcl-2 protein was seen in normal thyroid areas, encapsulated
FVPTC and PMC as compared to metastatic PTC. Metastatic PTC shows higher prolifera-
tion than other types of PTC but unexpectedly also higher apoptotic levels. Similar results
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were also seen with unencapsulated FVPTC, thus suggesting that unencapsulated FVPTC
has a potential for adverse outcome. Bcl-2 was immunolabeled in a low percentage of cells
in WDT-UMP.
Conclusions
The expression of the proliferative protein pHH3 together with the apoptotic marker cleaved
caspase-3 may indicate an aggressive behaviour of PTC and loss of apoptosis inhibition by
bcl-2 protein can further amplify the role of these proteins in tumor progression. Both cyclin
D1 and bcl-2 could prove to be interesting markers of PTC precursor lesions. Automated/
digital image quantification approach helps in refining the diagnostic accuracy.
Introduction
Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 85–
90% of all thyroid malignancies [1]. There has been an increasing trend in its incidence, which
may be attributed to early diagnosis and a concurrent increase in screening and surveillance
intensity.
Uncontrolled growth of cells is a hallmark of cancer and proliferation markers help in deci-
phering the proliferative potential of the cells. Although proliferation is now widely estimated
by the immunohistochemical assessment of the nuclear antigen Ki67, divergent results were
found by various groups in thyroid tumors [2–4]. Ki 67 is expressed during all active phases of
the cell cycle [1, 5], whereas phosphorylated histone H3 (pHH3) has emerged as a more spe-
cific marker of the mitotic phase as the antibody detects the core protein only when phosphor-
ylated at serine 10. Its immunolabeling allows to easily distinguish mitoses from their mimics
in hematoxylin and eosin stained histological sections and helps to confidently assess cell pro-
liferation [6, 7]. However, we believe that pHH3 immunolabeling has not yet been used to eval-
uate cell proliferation in PTC. Cell cycle progression is brought about by cyclin-dependent
kinases (CDK) that are activated by cyclins including cyclin D1 and inactivated by CDK inhibi-
tors [8]. Located on chromosome 11q13, cyclin D1 proto-oncogene regulates G1 to S-phase
transition in varied cell types from different tissues and has been linked to aggressive behaviour
of PTC [9].
Proliferation and apoptosis are opposing processes by which the cell numbers are kept in a
delicate balance, essential for tissue homeostasis. Several studies have elucidated a link between
apoptosis and cell cycle control [10, 11]. Apoptotic cell death is mediated by caspases, with cas-
pase-3 being their predominant executioner, resulting in DNA fragmentation and nuclear dis-
integration [12]. Active caspase-3 immunolabeling helps to identify apoptotic cells in tissue
sections and is considered more effective than the TUNEL method or morphological assess-
ment [13]. We decided to evaluate apoptosis in PTC and its variants by immunolabeling active
caspase-3, which has been previously linked to the stage and aggressive nature of PTC [14].
Bcl-2 is a known inhibitor of apoptosis, and its over-expression may result in proliferation of
mutated cells normally scheduled for death [15]. Previous reports have suggested decrease in
bcl-2 expression in PTC as compared to normal tissue [16]. Since bcl-2 protein suppresses apo-
ptosis by preventing caspases to carry out the process, it became imperative to assess its immu-
nolabeling pattern in PTC. Study of all these biomarkers is thus likely to increase the
understanding of the biological basis of PTC [17].
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Recent years have seen rapid advancement in digital pathology with whole slide imaging
and automated quantification of the immunostained tissue sections [18]. We have recently
demonstrated that automated analysis leads to better validation and reproducibility of immu-
nohistochemical analyses [19]. The American Society of Clinical Oncology and the College of
American Pathologists have also approved HER2 image analysis in the evaluation of breast
cancer, further emphasizing the importance of digital pathology [20]. We, therefore decided to
use this technique to compare the proliferative and apoptotic levels of tumor cells in metastatic
PTC of classic type, in follicular variants of PTC (FVPTC), in papillary microcarcinomas
(PMC), and in putative PTC precursors, so-called ‘well differentiated tumors of uncertain
malignant potential’ (WDT-UMP). To the best of our knowledge, this is the first study that
provides an automated assessment of the proliferative capacity and apoptotic potential of cells
in these various types of PTC.
Materials and Methods
Patients and selection of cases
The study was approved by the Ethics Committee of the Université catholique de Louvain.
Cases of PTC and its variants were retrieved from surgical pathology files and 13 cases each of
FVPTC, PMC and metastatic PTC were selected along with WDT-UMP, as previously
reported [21]. WDT-UMP cases were selected according to criteria described by Williams [22].
The WDT-UMP cases were encapsulated follicular nodules with nuclear features partially
characteristic of PTC (i.e., focal nuclear clearing, occasional nuclear grooves, angulated nuclear
contours and overlapping nuclei) but the histologic features did not display classic malignant
characteristics. FVPTC were selected according to established criteria [23]. Out of the 13
FVPTC cases, seven cases were encapsulated FVPTC and six were unencapsulated FVPTC.
Strict criteria were applied for diagnosing encapsulated FVPTC [24]. PMC and infiltrative met-
astatic PTC were selected according to the criteria of the World Health Organization [25]. All
PMC were tumors measuring 1 cm or less in diameter with characteristic PTC type nuclear fea-
tures. Only the primary tumor was analyzed in metastatic PTC cases.
Histology and Immunohistochemistry
Formalin-fixed paraffin sections (5μm-thick) were heated at 60°C for 30 min. Deparaffinisation
was followed by blocking endogenous peroxidase activity with 3% hydrogen peroxide. A water
bath was heated with the staining dish containing 0.01M citrate buffer (pH 5.8) until tempera-
ture reaches 100°C. The slides were then put in the staining dish and antigen retrieval was per-
formed by boiling for 75 min. The water bath heating was then turned off and the slides were
allowed to cool for 20 min. Sections were then incubated in 0.05% Triton X-100, 0.05M Tris-
HCl, pH 7.4 containing 10% goat serum for 30 min to block non-specific binding. This was fol-
lowed by overnight incubation at room temperature with one of the following primary anti-
bodies: anti-cyclin D1 rabbit monoclonal antibody, diluted 1:25 (RM9104-R7, Thermo
Scientific, Fremont, CA, USA); anti-bcl-2 mouse monoclonal antibody, diluted 1:50 (M0887,
DakoCytomation); or at 4°C with anti-pHH3 rabbit polyclonal antibody, diluted 1:500 (06–
570, Millipore, Billerica, MA, USA), or with anti-active caspase-3 rabbit polyclonal antibody,
diluted 1:200 (G748A, Promega, Madison, WI, USA). Sections were washed and then incu-
bated with EnVision+ HRP System™ (DakoCytomation) for 60 min. All the immunohisto-
chemical stains were visualized with 3, 30-diaminobenzidine tetrahydrochloride (DAB) in a
hydrogen peroxide solution. Controls were incubated with 0.05M Tris-HCl, pH 7.4 containing
1% goat serum in place of the primary antibody, and no staining was observed.
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The apoptotic index was evaluated by counting apoptotic cells on sections stained with
hematoxylin and eosin, according to criteria described by Van de Schepop et al [26]. For each
case, a map of 100 fields was created at 400-fold magnification and apoptotic bodies were
counted in these 100 fields. Results were compared with the immunolabeling of active
caspase-3.
Evaluation of immunostaining
Sections were digitalized at a 20x magnification by SCN400 slide scanner (Leica, Wetzlar, Ger-
many). The tumor tissue in each section was delineated manually and care was taken to exclude
tissue folds, bubbles and artefacts from the analysis. Scanned slides were then quantified using
Tissue IA (Leica Biosystems, Dublin, Ireland).
Quantification included application of algorithms for nuclear (cyclin D1 and pHH3) or
cytoplasmic (bcl-2 and cleaved caspase-3) immunostaining. Color deconvolution was applied
to each pixel using hematoxylin and DAB matrices of the software. On the hematoxylin
matrice, nuclear parameters (size, heterogeneity, strength of nuclear counterstaining, nuclei
density) and cellular parameters (size and cell radius) were adjusted to determine the adequate
segmentation. On the DAB matrice, a threshold was adjusted for DAB detection according to
intensity (grey values from 0 to 255). These parameters were kept constant throughout the
study for each immunostaining.
Statistical analysis
One-way ANOVA test was performed to test the difference between variants of PTC and with
normal thyroid areas for each immunostaining. Mann-Whitney test was then applied to deter-
mine between which variants the difference was significant. Difference was considered signifi-
cant at p<0.05. Correlations were determined by Spearman’s rank correlation coefficient test.
Computations were performed and graphs were drawn using GraphPad Prism version 5.04 for
Windows (GraphPad Software, La Jolla, CA, USA).
Results
Proliferative activity was assessed by immunolabeling of pHH3 and cyclin D1 whereas apopto-
tic potential was evaluated by immunolabeling of cleaved caspase-3, and bcl-2. Representative
microphotographs are shown at Figs 1 and 2. Nuclear immunolabeling was seen for pHH3 and
cyclin D1 whereas cleaved caspase-3 and bcl-2 were detected in the cytoplasm. Cleaved cas-
pase-3 was seen in the cytoplasm and occasionally in the nucleus of some normal thyroid cells.
There was a strong positive correlation between the number of cells immunolabeled for cleaved
caspase-3 and the number of apoptotic cells manually counted on hematoxylin and eosin-
stained sections (r = 0.76, p<0.0001, S1 Fig). The normal thyroid tissue showed intense cyto-
plasmic immunolabeling of bcl-2. The average percentage of cells immunolabeled for each
marker in normal thyroid tissue and all the variants of PTC is shown in Table 1 whereas Figs
3–6 show the wide distribution of the percentage of immunolabeled cells in each tumor type.
Nevertheless, ANOVA test indicated a highly significant difference among all tumor types and
normal thyroid tissue for each marker (p<0.0001). Post-hoc non-parametric Mann-Whitney
test showed that normal thyroid tissue was significantly different (p<0.05) from every tumor
type for each marker, except for bcl-2 where significant difference was found only with encap-
sulated FVPTC and with metastatic PTC.
ANOVA test also showed a highly significant difference among all tumor types for each
marker when normal thyroid tissue was excluded from the analysis (p<0.0001). Indeed, meta-
static PTC appeared to contain significantly more cells immunolabeled for the proliferative
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Fig 1. Immunolabeling of proliferative markers.Representative microphotographs of phosphorylated
histone H3 (pHH3; 1) and cyclin D1 immunolabeling (2) in normal thyroid tissue (a) and the various types of
papillary thyroid carcinomas: encapsulated (b) and unencapsulated (c) follicular variant of papillary thyroid
carcinoma (FVPTC), well differentiated tumor of unknownmalignant potential (WDT-UMP; d), papillary
microcarcinoma (PMC; e) and metastatic papillary thyroid carcinoma (f). Bars correspond to 50 μm.
doi:10.1371/journal.pone.0148656.g001
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Fig 2. Immunolabeling of apoptosis markers.Representative microphotographs of cleaved caspase-3 (1)
and bcl-2 (2) immunolabeling in normal thyroid tissue (a) and the various types of papillary thyroid
carcinomas: encapsulated (b) and unencapsulated (c) follicular variant of papillary thyroid carcinoma
(FVPTC), well differentiated tumor of unknownmalignant potential (WDT-UMP; d), papillary microcarcinoma
(PMC; e) and metastatic papillary thyroid carcinoma (f). Bars correspond to 50 μm.
doi:10.1371/journal.pone.0148656.g002
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Table 1. Average immunolabeling levels of proliferative and apoptotic markers (% of total cells).
PTC variants pHH3 Cyclin D1 Caspase-3 Bcl-2
Normal thyroid 0.00 1.50 0.17 32.00
Encapsulated FVPTC 1.11 35.47 6.12 67.47
Unencapsulated FVPTC 5.06 65.58 9.04 29.27
WDT-UMP 3.25 40.13 6.20 17.92
PMC 2.01 30.90 5.44 52.59
Metastatic PTC 5.96 51.75 9.27 18.50
doi:10.1371/journal.pone.0148656.t001
Fig 3. Proportion of tumor cells immunolabeled for phosphorylated histone H3. The percentage of
tumor cells showing phosphorylated histone H3 immunolabeling is indicated in normal thyroid tissue and
each case of the various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular
variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknownmalignant potential
(WDT-UMP), papillary microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC).
Bars indicate the medians. *, p<0.05. The large asterisk above normal thyroid tissue indicates significant
difference between the normal tissue and any other variant of PTC.
doi:10.1371/journal.pone.0148656.g003
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marker pHH3 (Fig 3) than all other PTC variants except unencapsulated FVPTC. The propor-
tion of cells immunolabeled for cyclin D1 (Fig 4) was not different from any other PTC variant
but metastatic PTC contained more cells immunolabeled for the apoptotic marker cleaved cas-
pase-3 (Fig 5) and less for the anti-apoptotic bcl-2 (Fig 6) than PMC and encapsulated FVPTC.
The unencapsulated FVPTC also contained significantly more cells immunolabeled for the
proliferative marker pHH3 than encapsulated FVPTC and PMC (Fig 3) and less cells immuno-
labeled for the anti-apoptotic bcl-2 than encapsulated FVPTC (Fig 6). In addition, it contained
more cells immunolabeled for the proliferative marker cyclin D1 (Fig 4) and the apoptotic
marker cleaved caspase-3 than PMC (Fig 5). Unencapsulated FVPTC was not different from
metastatic PTC for any marker.
Finally, WDT-UMP appeared to contain more cells immunolabeled for the proliferative
marker pHH3 and less cells immunolabeled for the anti-apoptotic marker bcl-2 than PMC and
encapsulated FVPTC (Figs 3 and 6). There was no significant difference between PMC and
encapsulated FVPTC for any marker.
Fig 4. Proportion of tumor cells immunolabeled for cyclin D1. The percentage of tumor cells showing
cyclin D1 immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary
thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma
(FVPTC), well differentiated tumor of unknownmalignant potential (WDT-UMP), papillary microcarcinoma
(PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05.
The large asterisk above normal thyroid tissue indicates significant difference between the normal tissue and
any other variant of PTC.
doi:10.1371/journal.pone.0148656.g004
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Discussion
PTC is the most common endocrine malignancy with an array of architectural/morphological
variants. The present work addresses the functionality of proliferative and apoptosis-related
biomarkers in PTC variants by an automated morphometric analysis. To the best of our knowl-
edge, this is the only study till date to have made an automated assessment of proliferative and
apoptotic markers in these lesions.
Innovations and rapid strides in the field of information technology have given rise to mor-
phometric analyses of histological images, thereby improving our understanding of the biologi-
cal basis of cancer [27]. Slide digitalization and immunolabeling quantification reduce
subjectivity and inter-observer variability, provided quality guidelines are used for pre-analyti-
cal steps (delay before tissue fixation, fixation time, section thickness, . . .), immunostaining
Fig 5. Proportion of tumor cells immunolabeled for cleaved caspase-3. The percentage of tumor cells
showing cleaved caspase-3 immunolabeling is indicated in normal thyroid tissue and each case of the
various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary
thyroid carcinoma (FVPTC), well differentiated tumor of unknownmalignant potential (WDT-UMP), papillary
microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the
medians. *, p<0.05. The large asterisk above normal thyroid tissue indicates significant difference between
the normal tissue and any other variant of PTC.
doi:10.1371/journal.pone.0148656.g005
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technique and automated quantification since algorithms or color matrices may vary from one
company/laboratory to the other one [19]. Slide scanner calibration procedures optimize ‘illu-
mination’ and ‘white balance’, which are important parameters affecting image analysis. This
leads to high-throughput analysis with constant parameters, continuous data production and
better retrieval of results due to better traceability. Comparisons between automated and visual
quantification of immunolabeled slides were recently found encouraging [19]. As the accuracy
of these technologies improve, the allure and the appeal of digital pathology to be incorporated
in routine laboratories increase. The benefits of digital pathology like swift diagnostic opinion
for frozen sections, ease of transferring/sharing images, storing and retrieving slides for future
use, among others, far outweigh its few negatives. Increased scanning speeds, automated slide
loaders and ease of storage have given the required thrust to digital pathology in recent years,
Fig 6. Proportion of tumor cells immunolabeled for bcl-2. The percentage of tumor cells showing bcl-2
immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary thyroid
carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma (FVPTC), well
differentiated tumor of unknownmalignant potential (WDT-UMP), papillary microcarcinoma (PMC) and
metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05.
doi:10.1371/journal.pone.0148656.g006
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prompting the College of American Pathologists and Laboratory Quality Centre to publish
guidelines on validating whole slide imaging in diagnostic pathology laboratories [28].
The proliferative potential of the cells has been presented as a valuable tool to assess the
prognosis of thyroid tumors [29]. We have previously studied Ki 67 in a similar setting and
have found significant immunolabeling in metastatic PTC as compared to normal thyroid
areas, WDT-UMP, FVPTC and papillary microcarcinomas [21]. The present automated mor-
phometric study showed an increased proportion of pHH3 immunolabeled cells in metastatic
PTC and unencapsulated FVPTC compared to other types of PTC. This suggests a progression
in the proliferation rate of neoplastic cells according to evolution of PTC towards metastatic
potential. Furthermore, normal thyroid tissue did not show immunolabeling of pHH3, and few
cells were immunolabeled in benign adenomatoid nodules compared to all types of PTC (not
shown). The mitotic marker pHH3 is linked with chromatin condensation in late G2 and M
phases of the cell cycle [30]. We believe pHH3 immunolabeling has not been evaluated earlier
in thyroid tumors though it was found to be useful in providing prognostic information in mel-
anocytic lesions [31], bladder cancers [32] and also in invasive breast cancer patients with
lymph node metastases [33]. In our hands, pHH3 showed increased expression in tumors with
metastatic potential. However, there was no significant difference in the proportion of cells
immunolabeled for pHH3 between the unencapsulated FVPTC and the metastatic PTC, thus
suggesting that unencapsulated FVPTC has a potential for adverse outcome, as reported by
other authors [29, 34]. Cyclin D1 is a positive regulator of the progression from G1 to S phase
and its overexpression has been reported in various carcinomas [35] and also linked to aggres-
sive behaviour of thyroid neoplasms [36]. Cyclin D1 was identified as a strong candidate diag-
nostic marker for PTC and its variants, including PMC and the WDT-UMP lesion, helping to
identify it as a putative precursor lesion of PTC [21]. It can also serve as a diagnostic tool in
FNAC for early diagnosis of PTC [37]. In the present study, the proportion of cells immunola-
beled for cyclin D1 also increased in the different PTC variants as compared to normal thyroid
areas, as previously reported [21, 38], but was not significantly different between PTC variants,
except between unencapsulated FVPTC and PMC. Thus, proliferative markers like pHH3 but
not cyclin D1 show a progressively increased expression from PMC and encapsulated FVPTC
to lesions with metastatic potential, lending them a predictive prognostic value, even though
PTC has been reported to be an indolent tumor with low proliferation rates [39]. The addition
of pHH3 as a biomarker to determine the proliferative capacity in PTCs, along with other
markers like Ki67, can help in creation of a proliferation profile, which can be specific and eas-
ily reproducible.
Tumorigenesis is dominated by processes that control proliferation and apoptosis of cells
[40]. Cleaved caspase-3 leads to proteolysis and ultimately apoptosis of cells. Few studies
addressed cleaved caspase-3 in thyroid carcinomas, showing no predictive or prognostic role in
thyroid carcinomas [41, 42]. Some studies have also linked the expression of caspase-3 with
aggressiveness of the tumor in PTC [14]. Thanks to a sensitive and accurate automatic mor-
phometric analysis, we found a small but significant increase in the proportion of cells showing
cleaved caspase-3 immunolabeling in the metastatic PTC compared to encapsulated FVPTC
and in both metastatic PTC and unencapsulated FVPTC compared to PMC. Along with pHH3
immunolabeling, this result indicates that aggressive lesions show both high proliferation and
high apoptotic potential as well. Similar results have also been observed in other cancers [43,
44]. We also found a strong positive correlation between the apoptotic indices by cleaved cas-
pase-3 immunolabeling and manual counting of apoptotic cells, thereby confirming that
cleaved caspase-3 is a good apoptotic marker in PTC [13].
We also explored bcl-2, a well known inhibitor of apoptosis, in the various types of PTC. The
normal thyroid tissue showed intense cytoplasmic immunolabeling for bcl-2, and PMC and
Automated Analysis of Proliferation and Apoptosis in PTC
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encapsulated FVPTC demonstrated bcl-2 immunolabeling in more cells as compared to the
metastatic lesions, implying that the loss of bcl-2 expression could correlate with increasing
aggressive nature and adverse prognosis of thyroid neoplasms. The percentage of cells immuno-
labeled for bcl-2 was also lower in unencapsulated FVPTC compared to encapsulated FVPTC,
as well as surprisingly in WDT-UMP compared to encapsulated FVPTC or PMC, suggesting
that a large proportion of our WDT-UMP cases could be precursors of unencapsulated FVPTC.
There are few data in literature on the significance of bcl-2 immunolabeling in PTC. Müller-
Höcker [45] has reported that absence of bcl-2 staining could be an early event in the formation
of oncocytic neoplasms in the thyroid. Expression of bcl-2 as an early oncogenic event in medul-
lary thyroid carcinomas was also reported byWang et al. [46]. Our study also suggests that bcl-
2 could be an invaluable marker to track pathogenic progress of thyroid lesions.
The pro-apoptotic marker cleaved caspase-3 shows an increased immunostaining and the
anti-apoptotic marker bcl-2 a decreased expression in lesions with metastatic potential as com-
pared to PMC and encapsulated FVPTC, suggesting that apoptosis related to bcl-2 plays a role
in thyroid tumorigenesis. The putative PTC precursor lesion WDT-UMP surprisingly showed
higher proportion of cells immunolabeled for pHH3 and lower proportion of cells immunola-
beled for bcl-2 than encapsulated FVPTC and PMC, thus prompting further work to under-
stand the reason for this difference. We report high proliferation and high apoptotic rates in
metastatic PTC, a fact that has also been demonstrated previously in metastatic prostate can-
cers [43, 47], breast cancer [48] and pilomatrix carcinoma with lymph node metastases [49].
Wang et al [50] have demonstrated that increased apoptosis is indeed seen in malignant
tumors. Altogether, this suggests that the delicate interbalance between proliferation and apo-
ptosis is disrupted leading to tumorigenesis.
In summary, the immunolabeling of the proliferative protein pHH3 together with the apo-
ptotic marker cleaved caspase-3 may indicate an aggressive behaviour of PTC and loss of apo-
ptosis inhibition by bcl-2 protein can further amplify the role of these proteins in tumor
progression. Loss of bcl-2 expression in PTC with metastatic potential also indicates a predis-
position to unfavourable prognosis. The progress of malignancy and metastatic potential of the
cells can be well tracked by assessing the proliferative/apoptotic activity of the PTC cells, as
suggested by the present automated morphometric study. Automated/digital image quantifica-
tion approach helps in refining the diagnostic accuracy.
Supporting Information
S1 Fig. Correlation between cleaved caspase-3 immunolabeling and apoptotic cells. The left
panel shows a representative microphotograph of an apoptotic cell (arrow) whereas the right
panel shows the correlation between automated analysis of cleaved caspase-3 immunolabeling
(percentage) and manual counting of apoptotic cells (absolute values). Spearman’s correlation
coefficient was highly significant (p<0.0001).
(TIF)
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